Novo Nordisk/$NVO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Novo Nordisk

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Ticker

$NVO

Primary listing

NYSE

Industry

Pharmaceuticals

Headquarters

Bagsvaerd, Denmark

Employees

77,406

ISIN

US6701002056

Novo Nordisk Metrics

BasicAdvanced
$309B
18.87
$3.69
0.21
$1.18
2.35%

What the Analysts think about Novo Nordisk

Analyst ratings (Buy, Hold, Sell) for Novo Nordisk stock.

Bulls say / Bears say

Novo Nordisk's experimental obesity drug, amycretin, demonstrated superior weight loss results in early trials, with participants losing an average of 24.3% of their body weight on the highest dose, surpassing current market leaders. (ft.com)
The company has submitted an application to the European Medicines Agency for a higher dose of its obesity treatment, Wegovy, after clinical trials showed one in three participants achieved a weight loss of 25% or more. (reuters.com)
Novo Nordisk raised its full-year sales and operating profit outlook for the third time in 2023, reflecting strong demand for its weight-loss drug Wegovy and diabetes medication Ozempic in the United States. (investing.com)
Novo Nordisk's shares have fallen 27% in March 2025, marking its worst month since 2002, due to concerns over slowing growth for its obesity drug Wegovy and competition from Eli Lilly's Zepbound. (bloomberg.com)
The company ousted CEO Lars Fruergaard Jørgensen amid concerns that it is losing its first-mover advantage in the competitive obesity drug market, with shares down 32% year-to-date and 59% from their peak. (investing.com)
Novo Nordisk misjudged the U.S. market demand for its weight-loss drug Wegovy, leading to supply shortages and high out-of-pocket costs for patients, allowing competitors like Eli Lilly to gain market share. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jul 2025.

Novo Nordisk Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Novo Nordisk Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVO

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events
FAQs